{"id":1254,"date":"2022-01-18T07:19:48","date_gmt":"2022-01-18T07:19:48","guid":{"rendered":"https:\/\/www.unioviedo.es\/IUOPA\/?page_id=1254"},"modified":"2024-09-18T16:29:20","modified_gmt":"2024-09-18T14:29:20","slug":"neoplasias-hematologicas","status":"publish","type":"page","link":"https:\/\/www.unioviedo.es\/IUOPA\/investigacion\/neoplasias-hematologicas\/","title":{"rendered":"Neoplasias hematol\u00f3gicas"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #f8f8f8;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_2 1_2 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-center fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><style type=\"text\/css\">@media only screen and (max-width:1024px) {.fusion-title.fusion-title-1{margin-top:0px!important; margin-right:0px!important;margin-bottom:31px!important;margin-left:0px!important;}}@media only screen and (max-width:640px) {.fusion-title.fusion-title-1{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important; margin-left:0px!important;}}<\/style><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"font-size:14px;margin-top:0px;margin-right:0px;margin-bottom:31px;margin-left:0px;\"><h2 class=\"title-heading-left fusion-responsive-typography-calculated\" style=\"margin:0;font-size:1em;--fontSize:14;--minFontSize:14px;line-height:1.3;\"><strong>JEFE DE GRUPO<\/strong><br \/>\nTeresa Bernal del Castillo<\/p>\n<p><strong>LOCALIZACI\u00d3N<\/strong><br \/>\nServicio de Hematolog\u00eda, Hospital Universitario Central Asturias<br \/>\nAvda Roma s\/n<br \/>\n33011, Oviedo<\/h2><\/div><div class=\"fusion-separator\" style=\"align-self: flex-start;margin-right:auto;margin-bottom:30px;width:100%;max-width:100px;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#25afb4;border-top-width:2px;\"><\/div><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:7px;width:100%;\"><\/div><div class=\"fusion-text fusion-text-1\"><p><strong>L\u00cdNEAS DE INVESTIGACI\u00d3N<\/strong><\/p>\n<p>El Grupo de Investigaci\u00f3n en Neoplasias Hematol\u00f3gicas desarrolla proyectos de investigaci\u00f3n centrados en pacientes con trastornos del sistema hematopoy\u00e9tico, abarcando estudios epidemiol\u00f3gicos, cl\u00ednicos y estudios b\u00e1sicos con aplicaciones cl\u00ednicas.<\/p>\n<p>Las \u00e1reas de trabajo del grupo se articulan en torno a las siguientes l\u00edneas:<\/p>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:50% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 3.84%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 3.84%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 1;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.88%;margin-left : 2.88%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;margin-bottom : 6%;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_2 1_2 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-center fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div style=\"text-align:center;\"><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\"><img decoding=\"async\" width=\"400\" height=\"320\" title=\"PIB-neoplasias\" src=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2023\/06\/PIB-neoplasias.png\" data-orig-src=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2023\/06\/PIB-neoplasias.png\" alt class=\"lazyload img-responsive wp-image-2771\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27400%27%20height%3D%27320%27%20viewBox%3D%270%200%20400%20320%27%3E%3Crect%20width%3D%27400%27%20height%3D%27320%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2023\/06\/PIB-neoplasias-200x160.png 200w, https:\/\/www.unioviedo.es\/IUOPA\/wp-content\/uploads\/2023\/06\/PIB-neoplasias.png 400w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 1024px) 100vw, (max-width: 640px) 100vw, 400px\" \/><\/span><\/div><div class=\"fusion-separator\" style=\"align-self: flex-start;margin-right:auto;margin-bottom:120px;width:100%;max-width:100px;\"><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:50% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 3.84%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 3.84%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 1;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 2.88%;margin-left : 2.88%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;margin-bottom : 6%;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 70px;margin-top : 0px;padding-right : 30px;padding-bottom : 70px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ffffff;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-center\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_2 1_2 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-2\"><p><strong>L\u00ednea de Investigaci\u00f3n 1: Desarrollo cl\u00ednico, aplicaci\u00f3n y efectividad de nuevos f\u00e1rmacos en leucemias agudas, s\u00edndromes mielodispl\u00e1sicos, linfomas y trasplante de progenitores hematopoy\u00e9ticos (TPH).<\/strong><\/p>\n<p>El grupo ha acumulado experiencia en la realizaci\u00f3n de ensayos cl\u00ednicos durante m\u00e1s de 15 a\u00f1os, a lo largo de los cuales ha participado tanto en estudios promovidos por la industria farmac\u00e9utica como por las sociedades cient\u00edficas nacionales e internacionales m\u00e1s relevantes en las patolog\u00edas mencionadas: GESMD, PETHEMA, GEL-TAMO, EBMT, SIC. Adem\u00e1s de la colaboraci\u00f3n con estas entidades, el grupo realiza investigaciones independientes que eval\u00faan la efectividad de f\u00e1rmacos en poblaci\u00f3n no seleccionada.<\/p>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:50% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 3.84%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 3.84%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-2{width:100% !important;order : 0;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;order : 0;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_2 1_2 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-3\"><p><strong>L\u00ednea de Investigaci\u00f3n 2: Tratamiento de soporte en pacientes que reciben quimioterapia y trasplante de progenitores hematopoy\u00e9ticos (TPH).<\/strong><\/p>\n<p>El tratamiento de soporte incluye la prevenci\u00f3n y tratamiento de las complicaciones infecciosas y no infecciosas secundarias a los tratamientos antineopl\u00e1sicos, incluido el TPH. La mejora en supervivencia observada en pacientes con leucemias agudas a lo largo de las \u00faltimas 2 d\u00e9cadas es atribuible fundamentalmente a la mejora en las medidas de soporte. Esta mejora est\u00e1 vi\u00e9ndose amenazada por la aparici\u00f3n de bacterias multirresistentes, y de hecho, se calcula que en el a\u00f1o 2050 la multirresistencia producir\u00e1 m\u00e1s muertes que el propio c\u00e1ncer. Por ello, el estudio, prevenci\u00f3n y erradicaci\u00f3n de la multirresistencia es una l\u00ednea prioritaria del grupo.<\/p>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:50% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 3.84%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 3.84%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 70px;margin-top : 0px;padding-right : 30px;padding-bottom : 50px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ffffff;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_2 1_2 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-4\"><p><strong>L\u00ednea de investigaci\u00f3n 3: Estratificaci\u00f3n del pron\u00f3stico biol\u00f3gico y selecci\u00f3n de estrategias terap\u00e9uticas adaptadas al riesgo en neoplasias hematol\u00f3gicas<\/strong><\/p>\n<p>Las caracter\u00edsticas gen\u00e9ticas y cl\u00ednicas de cada individuo con un tumor hematol\u00f3gico determinan la probabilidad de respuesta a los tratamientos y la supervivencia tras el diagn\u00f3stico. En el seno del grupo trabajamos en la aplicaci\u00f3n de diferentes t\u00e9cnicas y su integraci\u00f3n en la cl\u00ednica con objeto de categorizar de la manera m\u00e1s exacta posible el pron\u00f3stico de cada individuo y ajustar el tratamiento en funci\u00f3n de su riesgo.<\/p>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-4{width:50% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-4 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 3.84%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 3.84%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_2 1_2 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-5\"><p><strong>L\u00ednea de investigaci\u00f3n 4: Estudio de la enfermedad m\u00ednima residual (EMR).<\/strong><\/p>\n<p>La persistencia de enfermedad residual tras quimioterapia y una vez se ha efectuado un TPH es altamente predictiva de reca\u00edda. La detecci\u00f3n de la enfermedad residual puede realizarse mediante diferentes t\u00e9cnicas y la informaci\u00f3n derivada de cada una de ellas debe ser integrada. El objetivo final de la detecci\u00f3n de EMR es prevenir la reca\u00edda mediante la introducci\u00f3n precoz de f\u00e1rmacos y\/o la aplicaci\u00f3n de estrategias de inmunomodulaci\u00f3n y terapia celular.<br \/>\n(*)<br \/>\nGESMD: Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos<br \/>\nPETHEMA: Programa Espa\u00f1ol para el Tratamiento de las Hemopat\u00edas Malignas<br \/>\nGEL-TAMO: Grupos Espa\u00f1ol de Linfoma y Trasplante de M\u00e9dula \u00f3sea<br \/>\nEBMT: European Bone Marrow Transplant Society<br \/>\nSIC: Sociedad Ib\u00e9rica de Citometr\u00eda<\/p>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-5{width:50% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-5 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 3.84%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 3.84%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-5{width:100% !important;order : 0;}.fusion-builder-column-5 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-5{width:100% !important;order : 0;}.fusion-builder-column-5 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 50px;margin-top : 0px;padding-right : 30px;padding-bottom : 50px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #f8f8f8;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-6\"><p><strong>BIOGRAF\u00cdA DEL JEFE DE GRUPO<\/strong><\/p>\n<p>La Dra. Teresa Bernal del Castillo obtuvo el t\u00edtulo de licenciada en Medicina por la Universidad de Oviedo en el a\u00f1o 1992, y es Doctora en Medicina por dicha Universidad desde el a\u00f1o 1998. Realiz\u00f3 la especializaci\u00f3n en Hematolog\u00eda y Hemoterapia en el Hospital Universitario Central de Asturias, y desde el a\u00f1o 1999 forma parte de la Secci\u00f3n Cl\u00ednica del Servicio de Hematolog\u00eda y Hemoterapia de dicho hospital. En el a\u00f1o 2013 se incorpor\u00f3 como profesora asociada al Departamento de Medicina de la Universidad de Oviedo.<\/p>\n<p>Desde la obtenci\u00f3n del t\u00edtulo de especialista ha mantenido una actividad asistencial e investigadora centrada en las neoplasias hematol\u00f3gicas, abarcando desde aspectos patogen\u00e9ticos hasta la identificaci\u00f3n de estrategias terap\u00e9uticas eficaces. As\u00ed mismo, forma parte de varios grupos cooperativos para el diagn\u00f3stico y tratamiento de neoplasias mieloide, y es vocal del Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos. Ha publicado m\u00e1s de 50 art\u00edculos en revistas internacionales.<\/p>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-6{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-6 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-6{width:100% !important;order : 0;}.fusion-builder-column-6 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-6{width:100% !important;order : 0;}.fusion-builder-column-6 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-4{ padding-top : 70px;margin-top : 0px;padding-right : 30px;padding-bottom : 70px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-5 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ffffff;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-text fusion-text-7\"><p><strong>PUBLICACIONES SELECCIONADAS<\/strong><\/p>\n<ul>\n<li>Casta\u00f1\u00f3n C, Fern\u00e1ndez Moreno A, Fern\u00e1ndez Verdugo AM, Fern\u00e1ndez J, Mart\u00ednez Ortega C, Alaguero M, Nicol\u00e1s C, Vilorio Marqu\u00e9s L, Bernal T.: \u201cThe Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukaemia\u201d. J Clin Med. Nov 15; 8(11). (2019) pii: E1985. doi: 10.3390\/jcm8111985.<\/li>\n<li>Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, Gonz\u00e1lez-Campos J, Chill\u00f3n M, Holowiecka A, Esteve J, Bergua J, Gonz\u00e1lez-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fern\u00e1ndez I, de la Serna J, Moreno MJ, P\u00e9rez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA, HOVON, PALG, and GATLA cooperative groups: \u201cAn analysis of the impact of CD56 expression in de novo acute promyelocytic leukaemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens\u201d. Leuk Lymphoma. 2019 Apr; 60 (4): 1030-1035. doi: 10.1080\/10428194.2018.1516875. Epub 2018 Oct 15<\/li>\n<li>Mart\u00ednez-Cuadr\u00f3n D, Montesinos P, Vellenga E, Bernal T, Salamero O, Holowiecka A, Brunet S, Gil C, Benavente C, Ribera JM, P\u00e9rez-Encinas M, De la Serna J, Esteve J, Rubio V, Gonz\u00e1lez-Campos J, Escoda L, Amutio ME, Arnan M, Arias J, Negri S, Low\u00ebnberg B, Sanz MA. \u201cLong-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy\u201d Leukemia. 2018 Jan; 32(1):21-29. doi: 10.1038\/leu.2017.178. Epub 2017 Jun 6.<\/li>\n<li>Paiva B, Vidriales MB, Sempere A, Tar\u00edn F, Colado E, Benavente C, Cedena MT, S\u00e1nchez J, Caballero-Velazquez T, Cord\u00f3n L, Garces JJ, Simoes C, Mart\u00ednez-Cuadr\u00f3n D, Bernal T, Botella C, Grille S, Serrano J, Rodr\u00edguez-Medina C, Algarra L, Alonso-Dom\u00ednguez JM, Amigo ML, Barrios M, Garc\u00eda-Boyero R, Colorado M, P\u00e9rez-Oteyza J, P\u00e9rez-Encinas M, Costilla-Barriga L, Sayas MJ, P\u00e9rez O, Gonz\u00e1lez-D\u00edaz M, P\u00e9rez-Sim\u00f3n JA, Mart\u00ednez-L\u00f3pez J, Sossa C, Orfao A, San Miguel JF, Sanz M\u00c1, Montesinos P; PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) cooperative study group. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia. 2021 Aug;35(8):2358-2370. doi: 10.1038\/s41375-021-01126-3. Epub 2021 Feb 1. PMID: 33526859<\/li>\n<li>Bernal T, Mart\u00ednez-Camblor P, S\u00e1nchez-Garc\u00eda J, de Paz R, Lu\u00f1o E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Ca\u00f1izo C, Tormo M, Bargay J, Valc\u00e1rcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038\/leu.2015.115. Epub 2015 May 6.<\/li>\n<li>Lorenzana N, Avila LF, Alonso S, Colado E, Bernal T. \u201dThe impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment\u201d. Ann Hematol. 2017 Nov;96(11):1833-1840. doi: 10.1007\/s00277-017-3091-x. Epub 2017 Aug 13.<\/li>\n<li>Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, Gonz\u00e1lez M, Vidriales B, S\u00e1nchez-Guijo FM, L\u00f3pez-Corral L, Lu\u00f1o E, del Ca\u00f1izo C. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. Leuk Res. 2014 May;38(5):551-6. doi: 10.1016\/j.leukres.2014.02.001. Epub 2014 Feb 10.<\/li>\n<\/ul>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-7{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-7 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-7{width:100% !important;order : 0;}.fusion-builder-column-7 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-7{width:100% !important;order : 0;}.fusion-builder-column-7 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-5{ padding-top : 70px;margin-top : 0px;padding-right : 30px;padding-bottom : 70px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-6 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-blend-mode: overlay;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-section-separator section-separator triangle fusion-section-separator-1\"><div class=\"fusion-section-separator-svg\" style=\"border-bottom:1px solid #f8f8f8;\"><div class=\"divider-candy-arrow bottom\" style=\"top:0px;border-top-color: #f8f8f8;\"><\/div><div class=\"divider-candy bottom\" style=\"bottom:-21px;border-bottom:1px solid #f8f8f8;border-left:1px solid #f8f8f8;\"><\/div><\/div><div class=\"fusion-section-separator-spacer\"><div class=\"fusion-section-separator-spacer-height\" style=\"height:1px;\"><\/div><\/div><style type=\"text\/css\">.fusion-section-separator-1 .fusion-section-separator-svg {margin-left:1.92%;margin-right:1.92%;}@media only screen and (max-width:1024px) {.fusion-section-separator-1 .fusion-section-separator-svg {margin-left:1.92%;margin-right:1.92%;}}@media only screen and (max-width:640px) {.fusion-section-separator-1 .fusion-section-separator-svg {margin-left:1.92%;margin-right:1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-8{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-8 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-8{width:100% !important;}.fusion-builder-column-8 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-8{width:100% !important;}.fusion-builder-column-8 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-6{ padding-top : 0px;margin-top : 0px;padding-right : 30px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-7 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e8e8e8;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-justify-content-center\" style=\"max-width:1216.8px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><style type=\"text\/css\">@media only screen and (max-width:1024px) {.fusion-title.fusion-title-2{margin-top:0px!important; margin-right:0px!important;margin-bottom:31px!important;margin-left:0px!important;}}@media only screen and (max-width:640px) {.fusion-title.fusion-title-2{margin-top:0px!important; margin-right:0px!important;margin-bottom:20px!important; margin-left:0px!important;}}<\/style><div class=\"fusion-title title fusion-title-2 fusion-sep-none fusion-title-center fusion-title-text fusion-title-size-two\" style=\"font-size:60px;margin-top:0px;margin-right:0px;margin-bottom:31px;margin-left:0px;\"><h2 class=\"title-heading-center fusion-responsive-typography-calculated\" style=\"margin:0;font-size:1em;color:#ffffff;--fontSize:60;line-height:1.3;\">Miembros<\/h2><\/div><div class=\"fusion-separator\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:30px;width:100%;max-width:100px;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#ffffff;border-top-width:2px;\"><\/div><\/div><div class=\"fusion-text fusion-text-8\"><table width=\"100%\">\n<tbody>\n<tr>\n<td width=\"179\"><strong>Nombre<\/strong><\/td>\n<td width=\"108\"><strong>Cargo<\/strong><\/td>\n<td width=\"252\"><strong>E-mail<\/strong><\/td>\n<td width=\"80\"><strong>Tel\u00e9fono<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>Teresa Bernal del Castillo<\/strong><\/td>\n<td>Jefe de Grupo<\/td>\n<td><a href=\"mailto:bernalmaria@uniovi.es\">bernalmaria@uniovi.es<\/a><\/td>\n<td>985108000\/ext 39179<\/td>\n<\/tr>\n<tr>\n<td>Laura Vilorio Marqu\u00e9s<\/td>\n<td>Investigadora b\u00e1sica<\/td>\n<td><a href=\"mailto:lauvilmar@gmail.com\">lauvilmar@gmail.com<\/a><\/td>\n<td>985652433\/ext 38524<\/td>\n<\/tr>\n<tr>\n<td>Ahinoa Fernandez Moreno<\/td>\n<td>Investigadora cl\u00ednica<\/td>\n<td><a href=\"mailto:aftorozo@gmail.com\">aftorozo@gmail.com<\/a><\/td>\n<td>985108000\/ext 38289<\/td>\n<\/tr>\n<tr>\n<td>Jose Mar\u00eda Garc\u00eda Aznar<\/td>\n<td>Investigador predoctoral<\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>Christelle Casta\u00f1on<\/td>\n<td>Investigadora predoctoral<\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:20px;width:100%;\"><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-9{width:100% !important;margin-top : 0px;margin-bottom : 0px;}.fusion-builder-column-9 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-9{width:100% !important;}.fusion-builder-column-9 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-9{width:100% !important;}.fusion-builder-column-9 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style><\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-7{ padding-top : 70px;margin-top : 0px;padding-right : 30px;padding-bottom : 70px;margin-bottom : 0px;padding-left : 30px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":15,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-1254","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/pages\/1254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/comments?post=1254"}],"version-history":[{"count":8,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/pages\/1254\/revisions"}],"predecessor-version":[{"id":3845,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/pages\/1254\/revisions\/3845"}],"up":[{"embeddable":true,"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/pages\/15"}],"wp:attachment":[{"href":"https:\/\/www.unioviedo.es\/IUOPA\/wp-json\/wp\/v2\/media?parent=1254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}